Skip to main content
SanofiPartnership

Sanofi Sinks Toward 52-Week Low as Regeneron Deal Raises Cost Questions

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi and Regeneron have expanded their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to their alliance.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world. "This is a deliberate first step in igniting Sanofi's innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses," said Belén Garijo, Chief Executive Officer of Sanofi. "By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi's long-term future." Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Amount named
$1B
Stories
2
Takes effect
Oct 1, 2026
Location
Paris, Île-de-France, France

Companies

The full record

From the Signal API record

Numbers

Amount named in the story
$1B
Stories about this event
2

Extraction

Confidence
100%
Detected
Oct 1, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0948d53a-e882-5bcd-ea50-82e7cbf9cf83 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "0948d53a-e882-5bcd-ea50-82e7cbf9cf83",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-01T05:00:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/01/3372517/0/en/press-release-sanofi-and-regeneron-expand-global-alliance-with-multiple-next-generation-long-acting-immunology-antibodies.html",
    "title": "Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies",
    "excerpt": "Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world. “This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses,” said Belén Garijo , Chief Executive Officer of Sanofi. “By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.” Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting...",
    "summary": "Sanofi and Regeneron have expanded their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to their alliance.",
    "location": "Paris, France",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf",
    "confidence": 1,
    "published_at": "2026-10-01T05:00:00Z",
    "location_data": [
      {
        "city": "Paris",
        "state": "Île-de-France",
        "region": "Western Europe",
        "country": "France",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-01",
    "article_sentence": "Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation.",
    "related_company_name": "Regeneron Pharmaceuticals, Inc.",
    "related_company_domain": "regeneron.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.